pCR

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy 1 3.97 [2.15; 7.36], 1 RCT, I2=0%
unassessable degree of certainty